{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"409","value":"93.1"}]}],"title":"IFN-Ɣ: Cycle 1 Week 1 (N=184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.1","value":"27.4"}]}],"title":"IFN-Ɣ: Cycle 1 Week 2 (N=175)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.8","value":"22.8"}]}],"title":"IFN-Ɣ: Cycle 2 Week 1 (N=95)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.6","value":"21.6"}]}],"title":"IFN-Ɣ: Cycle 3 Week 1 (N=41)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"822","value":"589"}]}],"title":"IL-10: Cycle 1 Week 1 (N=184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"136","value":"95.7"}]}],"title":"IL-10: Cycle 1 Week 2 (N=175)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"633","value":"397"}]}],"title":"IL-10: Cycle 2 Week 1 (N=95)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"941","value":"428"}]}],"title":"IL-10: Cycle 3 Week 1 (N=41)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.6","value":"24.7"}]}],"title":"IL-2: Cycle 1 Week 1 (N=184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.21","value":"10.8"}]}],"title":"IL-2: Cycle 1 Week 2 (N=175)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.17","value":"11"}]}],"title":"IL-2: Cycle 2 Week 1 (N=95)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.03","value":"10.3"}]}],"title":"IL-2: Cycle 3 Week 1 (N=41)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2390","value":"826"}]}],"title":"IL-6: Cycle 1 Week 1 (N=184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"681","value":"234"}]}],"title":"IL-6: Cycle 1 Week 2 (N=175)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"952","value":"315"}]}],"title":"IL-6: Cycle 2 Week 1 (N=95)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"114","value":"69.2"}]}],"title":"IL-6: Cycle 3 Week 1 (N=41)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"125","value":"30"}]}],"title":"TNF-α: Cycle 1 Week 1 (N=184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.33","value":"10.3"}]}],"title":"TNF-α: Cycle 1 Week 2 (N=175)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15","value":"12.1"}]}],"title":"TNF-α: Cycle 2 Week 1 (N=95)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.79","value":"12"}]}],"title":"TNF-α: Cycle 3 Week 1 (N=41)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"description":"The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN)-γ using enzyme-linked immunosorbent assays or cytometric bead assays. The limit of detection of the assay (LOD) was 20 pg/mL and the limit of quantification (LOQ) was 125 pg/mL. Data below LOD were set to 10 pg/mL while data \\< LOQ and \\> LOD were reported as measured.\n\nSerum IL-4 levels were below detection limit (\\< 20 pg/mL) at all time points in all participants studied.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEAN","populationDescription":"Pharmacodynamic Data Set (PDS): All patients who received any infusion of blinatumomab and had at least one pharmacodynamic sample collected. N indicates the number of participants with available data at each time point.","reportingStatus":"POSTED","timeFrame":"Serum samples were collected on Days 1 and 8 at 2 hours and 6 hours after treatment start, and on Day 2 (24 hours) and Day 3 (48 hours) of each treatment cycle and on Days 9 and 10 after dose step.","title":"Serum Cytokine Peak Levels","type":"SECONDARY","unitOfMeasure":"pg/mL"}